HIV vaccine Ad4-EnvC150 - PaxVax
Alternative Names: Ad4-env Clade C; Ad4-EnvC150 vaccine; Adenovirus4 HIV EnvC150 vaccineLatest Information Update: 27 Mar 2024
At a glance
- Originator PaxVax
- Class AIDS vaccines; DNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 18 Mar 2024 PaxVax and National Institute of Allergy and Infectious Diseases (NIAID) terminates a phase I trial in HIV infections (Prevention) in USA (PO, Capsule), as study endpoints not met (NCT02771730)
- 28 Apr 2021 No recent reports of development identified for phase-I development in HIV-infections(Prevention, In volunteers) in USA (PO, Capsule)
- 28 Apr 2021 No recent reports of development identified for phase-I development in HIV-infections(Prevention, In volunteers) in USA (PO, Liquid)